Attached files
| file | filename |
|---|---|
| EX-10.7 - EXHIBIT 10.7 - OPIANT PHARMACEUTICALS, INC. | v476254_ex10-7.htm |
| EX-32.1 - EXHIBIT 32.1 - OPIANT PHARMACEUTICALS, INC. | v476254_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - OPIANT PHARMACEUTICALS, INC. | v476254_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - OPIANT PHARMACEUTICALS, INC. | v476254_ex31-1.htm |
| EX-21.1 - EXHIBIT 21.1 - OPIANT PHARMACEUTICALS, INC. | v476254_ex21-1.htm |
| EX-10.52 - EXHIBIT 10.52 - OPIANT PHARMACEUTICALS, INC. | v476254_ex10-52.htm |
| EX-10.9 - EXHIBIT 10.9 - OPIANT PHARMACEUTICALS, INC. | v476254_ex10-9.htm |
| EX-10.6 - EXHIBIT 10.6 - OPIANT PHARMACEUTICALS, INC. | v476254_ex10-6.htm |
| EX-10.5 - EXHIBIT 10.5 - OPIANT PHARMACEUTICALS, INC. | v476254_ex10-5.htm |
| 10-K - 10-K - OPIANT PHARMACEUTICALS, INC. | v476254_10k.htm |
EXHIBIT 32.2
CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Opiant Pharmaceuticals, Inc. (the “Company") for the year ended July 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, David D. O’Toole, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: October 13, 2017
| By: | /s/ David D. O’Toole | ||
| David D. O’Toole | |||
| Chief Financial Officer | |||